Osborn Lab
The overarching goal of Dr. Osborn’s laboratory is the development of novel approaches to modulate the autonomic nervous system for the treatment of cardiometabolic diseases. Although the primary focus of his research has been on hypertension, his laboratory is also interested in the role of autonomic dysfunction in metabolic conditions such as diabetes and obesity. His research has been continuously funded by NIH since 1988 and is currently focused in two areas.
1) Translational research on the contribution of renal nerves to the pathogenesis and maintenance of hypertension
This is the primary focus of the Osborn lab. Studies conducted in small (mice and rats) and large (sheep) models are investigating renal neural-immune interactions in hypertension. This research is currently funded by two NIH grants for which Dr. Osborn serves as the PI;
”Afferent renal nerves, renal inflammation, and hypertension” (R01 HL116476) and “A novel electroceutical tool for treatment of kidney-based diseases” (R21 DK128663).
In addition, the UMN is a clinical trial site on the use of catheter based renal nerve ablation to treat drug resistant hypertension. Dr. Osborn serves as the PI for the UMN site. “A pivotal, multicenter, blinded sham procedure-controlled trial of renal denervation by the Peregrine Catheter System Kit, in subjects with hypertension” (Ablative Solutions). | 
